Lactulose vs Polyethylene Glycol for Treatment of Hepatic Encephalopathy-Reply.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

1. Proceedings from the 2018 Canadian Association for the Study of the Liver Single Topic Conference-Decompensated cirrhosis: from clinic to transplant.Canadian liver journal · 2019
   Review

Corrections and comments

• Comment on
  Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.2014
• Comment on
  Lactulose vs Polyethylene Glycol for Treatment of Hepatic Encephalopathy.2015
• Comment on
  Lactulose vs Polyethylene Glycol for Treatment of Hepatic Encephalopathy.2015
• Erratum issued
  Missing signature block and author affiliations for in reply letter.2015

Authors and funding

3 authors at 3 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as